137 related articles for article (PubMed ID: 33559352)
21. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.
Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P
Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240
[TBL] [Abstract][Full Text] [Related]
22. The association between concerns toward adverse reactions during pre-approval drug reviews and the post-approval addition of clinically significant adverse reactions to package inserts: A retrospective analysis of pre-approval drug review reports and safety updates.
Watanabe K; Murakami M; Masuyama K; Ishiguro C; Matsuda T
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1265-1276. PubMed ID: 30252199
[TBL] [Abstract][Full Text] [Related]
23. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
24. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
[TBL] [Abstract][Full Text] [Related]
25. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
[TBL] [Abstract][Full Text] [Related]
26. Consistency in the safety labeling of bioequivalent medications.
Duke J; Friedlin J; Li X
Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):294-301. PubMed ID: 23042584
[TBL] [Abstract][Full Text] [Related]
27. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.
Fang H; Su Z; Wang Y; Miller A; Liu Z; Howard PC; Tong W; Lin SM
Clin Pharmacol Ther; 2014 May; 95(5):496-8. PubMed ID: 24448476
[TBL] [Abstract][Full Text] [Related]
28. Postmarketing Safety-Related Modifications of Drugs Approved by the US Food and Drug Administration Between 1999 and 2014 Without Randomized Controlled Trials.
Shepshelovich D; Tibau A; Goldvaser H; Ocana A; Seruga B; Amir E
Mayo Clin Proc; 2019 Jan; 94(1):74-83. PubMed ID: 30611457
[TBL] [Abstract][Full Text] [Related]
29. Interstitial Lung Disease as an Adverse Drug Reaction in Japan: Exploration of Regulatory Actions as a Basis for High Reporting.
Iwasa E; Fujiyoshi Y; Kubota Y; Kimura R; Chandler RE; Taavola H; Norén GN; Wakao R
Drug Saf; 2020 Nov; 43(11):1121-1131. PubMed ID: 32617874
[TBL] [Abstract][Full Text] [Related]
30. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
[TBL] [Abstract][Full Text] [Related]
31. Differences between the United States and Japan in labels of oncological drugs.
Jayaputra K; Ono S
Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):143-151. PubMed ID: 27670850
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of FDA safety-related drug label changes in 2010.
Lester J; Neyarapally GA; Lipowski E; Graham CF; Hall M; Dal Pan G
Pharmacoepidemiol Drug Saf; 2013 Mar; 22(3):302-5. PubMed ID: 23280652
[TBL] [Abstract][Full Text] [Related]
33. Impact of Expanded Access on FDA Regulatory Action and Product Labeling.
Jarow JP; Moscicki R
Ther Innov Regul Sci; 2017 Nov; 51(6):787-789. PubMed ID: 30079277
[TBL] [Abstract][Full Text] [Related]
34. Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.
Bailey S; Singh A; Azadian R; Huber P; Blum M
Drug Saf; 2010 Feb; 33(2):139-46. PubMed ID: 20082540
[TBL] [Abstract][Full Text] [Related]
35. Streamlining Considerations for Safety Measures: A Predictive Model for Addition of Clinically Significant Adverse Reactions to Japanese Drug Package Inserts.
Watanabe T; Ambe K; Tohkin M
Biol Pharm Bull; 2024; 47(3):611-619. PubMed ID: 38479885
[TBL] [Abstract][Full Text] [Related]
36. Factors distinguishing important identified risks from important potential risks in orphan and nonorphan drugs: An analysis of safety specifications of Japan and European Union risk management plans.
Hirota S; Yamaguchi T
Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1231-1238. PubMed ID: 30187590
[TBL] [Abstract][Full Text] [Related]
37. Safety monitoring of drugs receiving pediatric marketing exclusivity.
Smith PB; Benjamin DK; Murphy MD; Johann-Liang R; Iyasu S; Gould B; Califf RM; Li JS; Rodriguez W
Pediatrics; 2008 Sep; 122(3):e628-33. PubMed ID: 18762496
[TBL] [Abstract][Full Text] [Related]
38. Summaries of Safety Labeling Changes Approved By FDA--Boxed Warnings Highlights July--September 2015.
Am J Health Syst Pharm; 2015 Dec; 72(23):2008. PubMed ID: 26581924
[No Abstract] [Full Text] [Related]
39. Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.
Botelho SF; Martins MA; Vieira LB; Reis AM
J Clin Pharmacol; 2017 Apr; 57(4):493-499. PubMed ID: 27568487
[TBL] [Abstract][Full Text] [Related]
40. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
